Healthcare / BiotechnologyNasdaqCM
$4.43
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-113.9M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$418M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.5%
↓Gross Margin
N/A
•Debt/Equity
0.40
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.1M · net income $-79.2M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $35.1M | $35.1M | $2.6M | $0.00 | $0.00 | $0.00 | $3.0M | $0.00 | $0.00 | — | — |
| Net Income | $-79.2M | $-79.2M | $-37.5M | $-101.2M | $-93.9M | $-88.7M | $-62.1M | $-52.8M | $-33.3M | $-22.0M | $-23.0M |
| EBITDA | $-85.6M | $-85.6M | $-35.6M | $-107.1M | $-87.1M | $-84.6M | $-59.5M | $-51.6M | $-29.0M | $-22.2M | $-24.1M |
| EPS | -1.87 | -1.87 | -5.59 | -17.07 | -1.52 | -3.99 | -3.09 | — | — | — | — |
| Operating Margin | -247.4% | -247.4% | -1423.6% | — | — | — | -1995.8% | — | — | — | — |
| Net Margin | -225.6% | -225.6% | -1464.6% | — | — | — | -2071.0% | — | — | — | — |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.40 | 0.40 | 3.39 | 1.07 | 0.44 | 0.51 | 0.46 | 0.15 | -0.11 | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | — | — | $-131.2M | $-96.6M | $-77.2M | — | — | — | — | — | — |
| Returns | |||||||||||
| ROE | -42.5% | -42.5% | -169.1% | -198.0% | -126.8% | -137.7% | -85.3% | -40.9% | 43.2% | 49.4% | 99.7% |
| Growth & Yield | |||||||||||
| Revenue Growth | 1273.2% | 1273.2% | — | — | — | -100.0% | — | — | — | — | — |
| EPS Growth | 66.5% | 66.5% | 67.3% | -1023.0% | 61.9% | -29.1% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.